Subject: BCTXF's Lead Product Gains Valuable Attention at World’s Largest Gathering of Oncology Physicians

SCV Client Spotlight
BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement., Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence.
Facebook Twitter YouTube
BCTXF's Lead Product Gains Valuable Attention at World’s Largest Gathering of Oncology Physicians
Hot Stock to WatchHot Stock to Watch

Company: BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX-V: BCT)


Price: 0.12

Change (%): + 0.00 (0.00)

Volume: 0

Dr. Williams, BriaCell Therapeutics Corp.’s President & CEO, Discusses Recent News and Progress in an Exclusive New Audio Interview with

AUSTIN, Texas, June 13, 2018 (GLOBE NEWSWIRE) -, Inc. and BriaCell Therapeutics Corp. ("BriaCell") (TSX-V:BCT.V) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today that the Company’s President & CEO, Dr. Bill Williams, is featured in a new audio interview at, Inc.

The new BriaCell interview can be heard at

Dr. Bill Williams, BriaCell’s President & CEO, called in to, Inc. to discuss the importance of the Company’s recent clinical findings as published in the American Society of Clinical Oncology (ASCO) Annual Meeting Proceedings. ASCO’s Annual Meeting represents the world’s largest gathering of oncology physicians, biotechnology executives, researchers, and investment analysts to discuss breakthrough clinical research and therapeutics in the field. Additionally, Dr. Williams discusses the significance of the novel mechanism of action of BriaCell’s lead product candidate, Bria-IMT™ which has been recently published in the journal of Frontiers in Immunology, the 5th most cited journal in Immunology.

Continue Reading

Like Us on FacebookFollow Us on Twitter

SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks